This event is now closed, information is displayed here for information only.
The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017
but you can pre-register HERE to be advised when the programme is released

 

A one day meeting to be held on
Monday 28th November 2016
The Royal College of Physicians, London, UK

PROGRAMME


Chairs

Professor Daniel Hochhauser
Professor Daniel Hochhauser
Kathleen Ferrier Professor &
Co-Director CRUK UCL
Cancer Centre
Professor Tim Meyer
Professor Tim Meyer
Professor of Experimental
Cancer Medicine
UCL Cancer Institute

08.00 Registration & Coffee
09.00 Welcome / setting the scene: the Chairmen
SESSION 1: Genomics and Epigenomics of Gastrointestinal Cancer
09.05 Introduction
09.10 Molecular genetics of liver cancer
Professor Jessica Zucman-Rossi
Professor of Medicine, Oncology Department, University Paris Descartes-HEGP; Director of the ‘Functional genomics of solid tumors’ Unit, Inserm; & Chairman of the ‘Genetic, Epigenetic and Cancer’ scientific committee, Inserm, Paris, France
09.40 Epigenetics/ Neuroendocrine cancer
Dr Chrissie Thirlwell
Consultant Medical Oncologist, Research Department of Oncology, UCL Cancer Institute, London, UK
10.00 Colorectal cancer & genetic heterogeneity
Dr Trevor Graham
Lecturer in Tumour Biology, Bart’s Cancer Institute, London, UK
10.20 Summary
10.25 Break
SESSION 2: Novel Diagnostics in Gastrointestinal Cancer
10.55 Introduction
11.00 Circulating Tumour Cells in diagnostics/therapy
Professor Tim Meyer
Professor of Experimental Cancer Medicine and Consultant in Medical Oncology, Research Department of Oncology, University College London
11.20 3D Histopathology as a Novel Approach to Early Oesophageal Cancer Diagnosis
Dr Marnix Jansen
Physician Scientist with CRUK; Consultant histopathologist at University College London
11.40 Molecular Imaging of GI cancer
Professor Tony Ng
Richard Dimbleby Chair of Cancer Research, KCL Division of Cancer Studies and Randall Division; Professor of Molecular Oncology, UCL Cancer Institute, London, UK
12.00 Novel Radiological Approaches
Dr Shonit Punwani
Radiologist and Senior Lecturer in Clinical and Academic MRI, UCL
12.20 Summary
12.25 Lunch
SESSION 3: New Paradigms for Trials in Gastrointestinal Cancer
13.25 Introduction
13.30 Biliary tract cancers
Professor John Bridgewater
Professor of Medical Oncology, Research Department of Oncology, UCL Cancer Institute, London, UK
13.50 Liver Cancer
Professor Josep Llovet
Professor of Research-ICREA, BCLC Group, Liver Unit, IDIBAPS-Hospital Clínic of Barcelona, Spain; Director of the HCC Research Program &Professor of Medicine, Mount Sinai School of Medicine, New York University, NY., USA
14.20 Pancreas Cancer
Professor Hemant Kocher
Professor of Liver & Pancreas Surgery, Bart’s Cancer Institute, London, UK
14.40 Summary
14.45 Break
SESSION 4: Emerging Strategies for Therapy of Gastrointestinal Cancer
15.15 Introduction
15.20 Integration of conventional and novel therapies in GI cancer
Professor Daniel Hochhauser
Co-Director of the Cancer Research UK-UCL Centre, and Kathleen Ferrier Professor & consultant medical Oncologist, University College London
15.40 Microrna in Gastrointestinal Cancer
Dr Nicola Valeri
Team Leader, Gastrointestinal Cancer Biology and Genomics Team, ICR, London
16.00 Immunotherapy in GI cancer
Dr Hendrik-Tobias Arkenau
Executive Medical Director, Sarah Cannon Research Institute, London
16.20 Stem cells in GI (pancreas) cancer
Professor Christopher Heeschen
Centre Lead, Centre for Stem Cells in Cancer & Ageing, Bart’s Cancer Institute, Queen Mary University of London
16.40 Summary & Close

Costs
The meeting costs will be underwritten by Pharmaceutical Industry sponsors and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

This meeting is organised by:

New UCL Logo2 800

ATL-new-logo-July-2015-800px

 

and endorsed and supported by:

TLO

TL

exhibiting:

The Frontiers of Oncology 2018 meetings are supported by grants from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.